Repository logo
 

EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells

Published version
Peer-reviewed

Type

Article

Change log

Authors

Krusche, B 
Ottone, C 
Clements, MP 
Johnstone, E 
Goetsch, K 

Abstract

Glioblastomas (GBM) are aggressive and therapy-resistant brain tumours, which contain a subpopulation of tumour-propagating glioblastoma stem-like cells (GSC) thought to drive progression and recurrence. Diffuse invasion of the brain parenchyma, including along preexisting blood vessels, is a leading cause of therapeutic resistance, but the mechanisms remain unclear. Here, we show that ephrin-B2 mediates GSC perivascular invasion. Intravital imaging, coupled with mechanistic studies in murine GBM models and patient-derived GSC, revealed that endothelial ephrin-B2 compartmentalises non-tumourigenic cells. In contrast, upregulation of the same ephrin-B2 ligand in GSC enabled perivascular migration through homotypic forward signalling. Surprisingly, ephrin-B2 reverse signalling also promoted tumourigenesis cell-autonomously, by mediating anchorage-independent cytokinesis via RhoA. In human GSC-derived orthotopic xenografts, EFNB2 knock-down blocked tumour initiation and treatment of established tumours with ephrin-B2-blocking antibodies suppressed progression. Thus, our results indicate that targeting ephrin-B2 may be an effective strategy for the simultaneous inhibition of invasion and proliferation in GBM.

Description

Keywords

Eph/ephrin, GBM, cancer biology, cancer stem cells, cell biology, human, mouse, perivascular invasion, Animals, Cell Movement, Cell Proliferation, Ephrin-B2, Glioblastoma, Heterografts, Humans, Intravital Microscopy, Mice, Neoplastic Stem Cells

Journal Title

eLife

Conference Name

Journal ISSN

2050-084X
2050-084X

Volume Title

5

Publisher

eLife Sciences Publications Ltd
Sponsorship
Medical Research Council (MC_PC_12009)
Medical Research Council (Cell Interactions and Cancer, MC_AS A652 5PZ10) Regional Government of Madrid (European Social Fund) The Royal Society (RG110360)